

REVIEW ARTICLE OPEN



Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

Hongge Liang ¹, Yan Xu¹, Jing Zhao ¹, Minjiang Chen¹ and Mengzhao Wang ¹✉

© The Author(s) 2024

Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the emergence of targeted therapy and immunotherapy revolutionized the treatment of NSCLC and greatly improved patients' survival. However, drug resistance is inevitable, and extensive research has demonstrated that the Hippo pathway plays a crucial role in the development of drug resistance in NSCLC. The Hippo pathway is a highly conserved signaling pathway that is essential for various biological processes, including organ development, maintenance of epithelial balance, tissue regeneration, wound healing, and immune regulation. This pathway exerts its effects through two key transcription factors, namely Yes-associated protein (YAP) and transcriptional co-activator PDZ-binding motif (TAZ). They regulate gene expression by interacting with the transcriptional-enhanced associate domain (TEAD) family. In recent years, this pathway has been extensively studied in NSCLC. The review summarizes a comprehensive overview of the involvement of this pathway in NSCLC, and discusses the mechanisms of drug resistance, potential targets, and biomarkers associated with this pathway in NSCLC.

Cancer Gene Therapy; <https://doi.org/10.1038/s41417-024-00761-z>

INTRODUCTION

Among malignant tumors worldwide, lung cancer has the highest mortality rate and the second-highest annual incidence, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [1]. Unfortunately, the majority of NSCLC patients are diagnosed at advanced stages, resulting in a poor prognosis for these individuals [2, 3]. Recently, several carcinogenic pathways have been identified in NSCLC, including mutations in the epidermal growth factor receptor (EGFR), fusion of the anaplastic lymphoma kinase (ALK), mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS), rearrangement of the ROS proto-oncogene 1 (ROS1), mutations in the B-Raf proto-oncogene (BRAF), fusion of the neurotrophin receptor kinase (NTRK), exon 14 skipping mutation in the c-mesenchymal-epithelial transition factor (c-MET), rearrangement of the rearranged during transfection proto-oncogene (RET), and mutations in the human epidermal growth factor receptor 2 (ERBB2/HER2). These pathways play a significant role in the development and progression of NSCLC. Currently, drugs developed for targeting these oncogenic pathways have been approved by the National Comprehensive Cancer Network (NCCN) guidelines for treating advanced NSCLC with corresponding genetic alterations [4, 5]. Furthermore, several phase III clinical trials have demonstrated significant and durable clinical benefits in advanced NSCLC patients through the application of immune checkpoint inhibitors (ICIs) that target programmed cell death-ligand 1 (PD-L1), programmed cell death 1 (PD-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). NCCN guidelines have approved atezolizumab (ICI targeting PD-L1), nivolumab (ICI targeting PD-1),

pembrolizumab (ICI targeting PD-1), and ipilimumab (ICI targeting CTLA-4) for treating NSCLC as they significantly prolong survival in some patients [5]. However, although targeted therapy and immunotherapy greatly improved the prognosis in some patients with NSCLC, after an initial positive response to treatment, it is inevitable that patients will eventually develop acquired drug resistance over time [6]. Previous studies have shown that the major effector factors of the Hippo pathway, namely Yes-associated protein (YAP) and transcriptional co-activator PDZ-binding motif (TAZ), play a key role in mediating drug resistance in NSCLC [7].

The Hippo pathway, initially identified in *Drosophila* and conserved throughout mammalian evolution, consists of key components in mammals including MST1 and MST2 (Ste20-like kinases 1 and 2), SAV1 (Salvador homolog-1) as their binding partner, LATS1 and LATS2 (large tumor suppressor kinase 1 and 2) along with their binding partners MOB1A/B (MOB Kinase Activator 1A and 1B), YAP, TAZ, and transcriptional-enhanced associate domain (TEAD) [8–10]. There are no designated ligands or receptors for the Hippo pathway [11]. The Hippo pathway can be activated by various signals, both from the extracellular and intracellular environment. These signals include cell-cell contact, the extracellular matrix (ECM), cell polarity, cell density, mechanical signals, intracellular tension, soluble factors, stress signals, cellular energy status, mitogens, changes in cellular metabolism, tyrosine kinase receptors, and ligands of G-protein-coupled receptors (GPCR), among others [11–15]. When the Hippo pathway is activated, MST1/2 and their adaptor protein SAV1 phosphorylate LATS1/2 [8, 16]. Once phosphorylated, LATS1/2 and

¹Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ✉email: mengzhaowang@sina.com

Received: 28 November 2023 Revised: 4 March 2024 Accepted: 7 March 2024

Published online: 18 March 2024




Fig. 1 Hippo pathway in cells. There are no designated ligands or receptors for the Hippo pathway. The Hippo pathway can be activated by various signals, including cell-cell contact, extracellular matrix (ECM), cell polarity, cell density, and mechanical signals. When the Hippo pathway is activated in healthy cells, MST1/2 and their adaptor protein SAV1 phosphorylate LATS1/2. Once phosphorylated, LATS1/2 and their adaptor MOB1A/B phosphorylate YAP and TAZ. These phosphorylation events lead to the sequestration of YAP and TAZ in the cytoplasm and promote their subsequent degradation. This sequestration and degradation can occur through the binding of YAP and TAZ to 14-3-3 proteins or the action of the ubiquitin ligase β TRCP-SCF complex, regulating organ size control, maintaining epithelial balance, modulating tissue regeneration, enhancing wound healing, and contributing to immune regulation in healthy tissues. On the other hand, when the Hippo pathway is dysregulated in cancer cells, YAP and TAZ undergo translocation into the nucleus, binding to TEAD1-4 proteins. TEAD1-4 brings YAP and TAZ to the appropriate DNA elements to upregulate proliferative molecules. Dysregulation of the Hippo pathway plays a key role in tumor progression, drug resistance, cancer immune evasion, metastasis, epithelial-mesenchymal transition, and stem cell-like properties. MST mammalian STE20-like protein kinase, LATS large tumor suppressor kinase, SAV1 Salvador homolog-1, MOB1A/B MOB Kinase Activator 1A and 1B, YAP Yes-associated protein, TAZ transcriptional co-activator PDZ-binding motif, TEAD transcriptional-enhanced associate domain, P phosphorylation.

their adaptor MOB1A/B phosphorylate YAP and TAZ. These phosphorylation events lead to the sequestration of YAP and TAZ in the cytoplasm and their subsequent degradation. This sequestration and degradation can occur through the binding of YAP and TAZ to 14-3-3 proteins or the action of the ubiquitin ligase β TRCP-SCF complex [11]. On the other hand, when the Hippo pathway is deactivated, YAP and TAZ undergo translocation into the nucleus, binding to TEAD1-4 proteins. TEAD1-4 brings YAP and TAZ to the appropriate DNA elements to upregulate proliferative molecules [8, 10, 11, 17]. The Hippo pathway regulates proliferation, cellular overgrowth, contact inhibition, stem cell function, tissue homeostasis, wound healing, apoptosis, differentiation, immune response, and regeneration in healthy tissues [10, 18–24]. In addition, the Hippo pathway plays a pivotal role in the development and progression of tumor [25, 26] (Fig. 1). The dysregulation of the Hippo signaling pathway results in the activation of YAP, which promotes the progression of various types of human cancers, including lung cancer, mesothelioma, breast cancer, liver cancer, neural tumors, gastric cancer, ovarian cancer, urogenital cancer, and skin cancer [27–36]. Previous studies have demonstrated the significant involvement of the Hippo pathway in drug resistance, cancer immune evasion,

metastasis, and epithelial-mesenchymal transition (EMT) in NSCLC [37–42]. Furthermore, reduced expression of LATS1 and increased expression of YAP are correlated with unfavorable prognosis in NSCLC [43, 44].

In order to gain a comprehensive understanding of the impact of the Hippo pathway on lung cancer, we conducted a search for articles related to the Hippo pathway and lung cancer on the Web of Science Core Collection (Supplementary Material S1 provides the keywords used in the search). A total of 1211 literature records were retrieved. Subsequently, a metrology analysis was performed on this collection of literature. The analysis revealed several key findings. The number of literature articles studying the interaction between lung cancer and the Hippo pathway has been increasing over the years (Fig. 2A). The existing studies primarily focused on the effects of Hippo pathway dysfunction on tumor proliferation, treatment resistance, and prognosis (Fig. 2B). In terms of research topics, the expression levels of YAP/TAZ in the Hippo pathway emerged as a current research hotspot. In addition, the investigation of drug resistance in lung cancer exhibited considerable research prospects (Fig. 2C). According to the research trends, the latest focus is on exploring the interaction mechanism between the Hippo pathway and related circular rRNA, followed by the




Fig. 2 Bibliometric analysis. **A** Annual Scientific Production indicated that the quantity of articles measuring the role of the Hippo pathway in lung cancer has steadily risen since 1991, with a significant surge in research from 2013. **B** Co-occurrence network revealed that current research predominantly focuses on the effects of the dysfunctional Hippo pathway on tumor proliferation, treatment resistance, and prognosis. Other areas of interest encompass the influence of the Hippo pathway on tumor growth, heterogeneity, apoptosis, metastasis and differentiation, etc. **C** Thematic map suggested that the current research focuses on the expression level of YAP and TAZ in the Hippo pathway. Furthermore, there is extensive research potential in exploring the role of the Hippo pathway in lung cancer resistance to radiotherapy and chemotherapy. **D** Trend topics indicated that over the last five years, research hotspots have primarily concentrated on the interaction between the Hippo pathway and related circular rRNA, the impact of the Hippo pathway on tumor heterogeneity, the classification of different tumor subtypes, inhibitors of the Hippo pathway, the effects of the Hippo pathway on tumor migration, and the expression levels of key components of the Hippo pathway.

impact of the Hippo pathway on tumor heterogeneity and the classification of different tumor subtypes (Fig. 2D). This article examines the pertinent studies on the Hippo pathway and emphasizes its significance in mechanisms of drug resistance, potential targets, and biomarkers in NSCLC (Fig. 3).

DYSREGULATION OF THE HIPPO PATHWAY IN NSCLC

Dysregulation of the Hippo pathway is of great significance in the initiation, progression, and metastasis of tumors, rendering it a promising therapeutic target. Accumulating preclinical and clinical findings indicate that the deficiency of upstream regulatory factors in the Hippo pathway or the overactivation of YAP/TAZ plays a role in tumor growth and metastasis [45] [11, 25]. Although the Hippo pathway is dysregulated in many cancer types, genetic alterations affecting this pathway are relatively rare and present in less than 10% of patients [26]. Oncogenic alterations of the Hippo pathway in NSCLC include neurofibromin 2 (NF2) mutation, NF2 fusion, LATS1/2 mutation, LATS1 fusion, YAP1/TAZ fusion, and YAP1/TAZ gene amplification [46–50]. Moreover, changes in the expression levels of key molecules in the Hippo pathway have been identified in NSCLC, potentially impacting the prognosis of NSCLC patients.

NF2

The NF2 gene, which encodes the Merlin protein, functions as a tumor suppressor and serves as a key negative regulator of the Hippo pathway. Its function contributes to the phosphorylation of MST and LATS, resulting in the cytoplasmic localization and degradation of YAP and TAZ [11, 51]. In addition, NF2 can regulate the palmitoylation of TEAD by controlling the expression of FASN, thereby inhibiting YAP/TAZ-induced transcription in response to cell contact [52]. Thus, loss-of-function mutations of NF2 can activate YAP/TAZ-TEAD, leading to the onset and progression of tumors [53]. Previous studies have shown that numerous acquired somatic mutations occur in NF2, particularly in meningioma, mesothelioma, and peripheral neurofibroma. These mutations are also found in other types of cancer, such as breast cancer, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and renal cell carcinoma [54, 55]. Patients with malignant mesothelioma harboring NF2 mutations respond to TEAD inhibitor [56]; however, the NF2 mutation rate in lung squamous cell carcinoma is only 2.2% [57]. In addition, NF2 fusion inhibiting NF2 function, including NF2-OSBP2 and NF2-MORC2-fusion, have been found in lung cancer [49]. Further research is required to determine the effectiveness of drugs that target the Hippo pathway in NSCLC patients with NF2 gene alterations.




Fig. 3 Hippo Pathway in NSCLC. The NF2 gene functions as a tumor suppressor and serves as a key negative regulator of the Hippo pathway. When the Hippo pathway is activated, MST1/2 and their adaptor protein SAV1 phosphorylate LATS1/2. Once phosphorylated, LATS1/2 and their adaptor MOB1A/B phosphorylate YAP and TAZ. These phosphorylation events lead to the sequestration of YAP and TAZ in the cytoplasm and their subsequent degradation. When the Hippo pathway is disrupted, YAP/TAZ enters the nucleus and binds to TEAD, leading to the expression of target genes. Dysregulation of the Hippo pathway in NSCLC mainly involves: (1) Gene alterations: including NF2 mutation, NF2 fusion, LATS1/2 mutation, LATS1/2 fusion, LATS1/2 amplification, YAP/TAZ fusion, YAP/TAZ amplification; (2) Protein expressions: nucleus YAP/TAZ/TEAD overexpression. Agents target Hippo Pathway in clinical trial IAG933, IK-930, VT3989, BPI-460372. Resistance Mechanisms: EGFR-TKI resistance mechanisms: YAP/TAZ-TEAD 1) synergize with oncogenic RIT1, 2) inhibit BMF transcription, 3) activate AXL, 4) regulate ROS/HIF-1 α axis and FOXM1, and 5) activate EGFR/RAS. BRAF-TKI resistance mechanism: YAP upregulate the expression of the anti-apoptosis Bcl-xL. KRAS-TKI resistance mechanisms: RASSF1A methylation synergically promote tumor growth by up-regulating YAP (to be confirmed). ALK-TKI resistance mechanisms: YAP 1) mediates the expression of the anti-apoptosis factors Mcl-1 and Bcl-xL, and 2) interact with SHP2 (to be confirmed). ROS1-TKI resistance mechanism: YAP regulate the AKT signaling pathway. ICI resistance mechanisms: 1) YAP upregulates PD-L1 and inhibit T cell function; 2) MST and LATS down-regulate PD-L1. Chemoradiotherapy 1) YAP/TAZ degradation \rightarrow increase chemotherapy resistance; 2) Increased YAP/TAZ \rightarrow activate AXL \rightarrow cisplatin resistance; 3) Increased YAP \rightarrow reduce radiotherapy sensitivity; 4) Increased TEAD2 \rightarrow reduce chemotherapy resistance. Small Molecule Compounds: Verteporfin, XAV939, MYF-01-37, IK-930, VT3989; Verteporfin; TW37, PLX4720; To be studied; Verteporfin; ICI combined with YAP inhibitors? (to be studied); Chemoradiotherapy combined with YAP inhibitors? (to be studied).

MST/LATS

The upstream components of the Hippo pathway, MST1/2 and LATS1/2, function as tumor suppressors by promoting the binding of YAP/TAZ and 14-3-3 through phosphorylation, leading to their cytoplasmic localization and degradation [58]. Genetic alterations or functional deletions of these molecules can promote the nuclear translocation of YAP and TAZ. Nuclear YAP and TAZ bind to the TEAD transcription factor family and trigger the expression of target genes, potentially contributing to the occurrence and development of tumors [59, 60]. Moreover, the copy number loss of LATS1/LATS2 has been documented in numerous cancer types, which was shown to increase cell proliferation in vitro [61, 62]. Furthermore, targeted therapy for the Hippo pathway is effective in tumors with LATS dysfunction. For example, the TEAD palmitoylation inhibitor IK-930 was effective in the CDX model of MSTO-211H mesothelioma with LATS deficiency [63]. In addition, gene fusions involving LATS1 and LATS2 have been found in lung cancer [49], and low expression level of LATS1 was associated with poor prognosis in patients with NSCLC [43]. Further studies are needed to investigate the effect of genetic changes in MST/LATS on the therapeutic efficacy of targeted therapy for Hippo pathway in NSCLC.

YAP/TAZ

YAP and TAZ serve as co-factors of several transcription factors. When the Hippo pathway is inactivated, YAP and TAZ translocate to the nucleus, where they form a complex with TEAD. They

contribute to the occurrence and progression of various tumors, such as lung cancer, breast cancer, liver cancer, colon cancer, and ovarian cancer [24, 27, 45, 54, 64, 65], by promoting cell survival, abnormal growth, and stem cell-like properties [25].

Activating mutations in YAP and TAZ are extremely uncommon in human cancer [54, 61, 66], and individual activation mutations of YAP and TAZ are insufficient to induce tumorigenesis, which may be related to the negative feedback loop associated with YAP and TAZ [67]. Nonetheless, the interaction of the Hippo pathway with the dysfunction of other pathways can trigger tumorigenesis [68]. For instance, increased YAP expression in type II alveolar epithelial cells only leads to hyperplasia in mouse lungs. However, ectopic YAP expression accelerates the progression of de novo lung cancer in the *Kras*^{G12D} mouse model [68]. In addition, YAP/TAZ fusions are the major causes of Hippo pathway dysregulation. These fusion events preserve the TEAD binding domain, and have the potential to promote the transcription of TEAD target genes, thereby enhancing tumor progression [69]. Fusions of YAP or TAZ with other genes, including TAZ-CAMTA1, YAP-MAML1, YAP-MAML2, YAP-FAM118B, YAP-KMT2A, YAP-TFE3, and YAP-NUTM1, have been reported in various rare tumors such as epithelioid hemangioendothelioma, glioma, supratentorial ependymoma, etc. Similarly, fusion events affecting key components of the Hippo pathway have been found in patients with lung cancer. For instance, fusions of oncogenic proteins TAZ, YAP1, and HIPK2 preserve their tumor-promoting function, while fusions of tumor suppressors, such as NF2, LATS1, FAT1, PTPN14, DCHS2, TAOK1,

and TAOK3, results in loss of their function [49]. The increased expression levels of YAP and TAZ are usually attributed to gene amplification [61] or decreased degradation through autophagosomes [70] and ubiquitin–proteasome degradation systems [71, 72]. Wang et al. [26] reported a combined amplification frequency of 0–19% for YAP and TAZ in 33 cancers, with lung squamous cell carcinoma ranking second. Besides, there is more YAP nucleus enrichment in NSCLC than in healthy tissues [73], which has a crucial function in maintaining NSCLC stemness [50]. Moreover, the overexpression levels of YAP and TAZ are associated with poor survival in patients with NSCLC [47, 48].

TEAD

As the primary partner in YAP/TAZ-mediated oncogenic transcription [74], the TEAD transcription factor family serves as the ultimate nuclear effector of the Hippo pathway and is widely expressed in human tissues [75, 76]. TEAD alone has almost no transcriptional activity and relies on transcriptional co-activators to trigger the expression of target genes [77]. Among them, the most established co-factors for activating TEAD are YAP and its paralog TAZ. The N-terminus of YAP/TAZ interacts with the C-terminus of TEAD, forming the YAP/TAZ-TEAD complex, which forms the nuclear transcription module of the Hippo pathway [11]. In addition, the activity of TEAD depends on its nuclear/cytoplasmic translocation [78] and palmitoylation [52, 79]. TEAD activation is crucial for tumor development, as it plays a vital role in tumor EMT, metastasis, drug resistance, and stem cell self-renewal [80–84]. So far, there are no oncogenic mutations have been identified for TEAD. However, several studies indicated that the nuclear preservation and activation of YAP and TAZ may rely on their interaction with TEAD [85, 86]. Previous studies have demonstrated that elevated TEAD expression and nuclear accumulation are associated with poorer overall survival in various cancer types, including breast cancer [87], rectal cancer [88], pancreatic ductal adenocarcinoma [89], and head and neck cancer [90]. These findings underscore the potential significance of TEAD in cancer prognosis. However, the effect of TEAD nuclear expression levels on the prognosis of NSCLC and its potential clinical application as a biomarker in NSCLC still need more studies.

Role of the Hippo pathway in resistance to targeted therapy in NSCLC

Studies have reported that disruptions in the Hippo pathway are correlated with unfavorable clinical outcomes in patients with NSCLC [44, 73]. Besides its role in tumorigenesis, the Hippo pathway plays a pivotal role in drug resistance of NSCLC via crosstalk with other well-known tumor-promoting factors such as EGFR, ALK, BRAF, KRAS, and ROS1 [91–98]. Several studies have shown that in NSCLC cells with gene alterations of KRAS G12C, BRAF V600E, EGFR, ALK, or ROS1, dysregulation of the Hippo pathway decreases the initial response to various tyrosine kinase inhibitors, which is associated with resistance of targeted therapy and tumor recurrence. YAP inhibition restored the sensitivity of NSCLC cells to targeted treatment in these studies [91, 93, 94, 97, 99, 100].

EGFR mutation

EGFR, a receptor belonging to the ErbB family, is encoded by EGFR exon 18–24. Mutations that activate the kinase domain of EGFR primarily occur at exon 18–21, leading to the activation of downstream signaling pathways such as Ras/Raf/MEK/ERK, Janus kinase (JAK)/STAT, and phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR. These mutations are strongly associated with human NSCLC [101–104]. The EGFR pathway has been well studied as an oncogenic pathway in NSCLC [105–109]. Patients with EGFR-sensitive mutations in NSCLC can experience therapeutic benefits from the use of EGFR-tyrosine kinase inhibitors (TKIs). These

include 1st-generation EGFR-TKIs (gefitinib and erlotinib), 2nd-generation EGFR-TKIs (dacomitinib and afatinib), and 3rd-generation EGFR-TKI (osimertinib) [98, 110–117]. Nevertheless, it is inevitable for patients undergoing EGFR-TKI treatment to eventually develop drug resistance, and it is essential to elucidate the mechanism of acquired resistance. Previous studies reported that EGFR-TKI resistance is associated with YAP overexpression or YAP amplification, and silencing YAP by siRNA can reverse EGFR-TKI resistance in NSCLC cells [40, 118]. Similarly, another study discovered that the increased expression of YAP in EGFR-mutated NSCLC cells led to resistance to EGFR-TKI (erlotinib), whereas the knockdown of YAP increased the sensitivity of NSCLC cells to erlotinib [99]. Meanwhile, clinical studies found that YAP overexpression was associated with NSCLC progression and poor clinical outcomes. Chaib et al. reported that increased expression of STAT3 or YAP1 was associated with poor progression-free survival (PFS) in NSCLC patients harboring EGFR mutation who received first-line EGFR-TKIs, suggesting that both Src-YAP axis and STAT3 can lead to a reduced response to EGFR-TKIs in lung cancer [100].

The interaction between the Hippo pathway and the EGFR signaling pathway in lung adenocarcinoma (LUAD) is intricate. Previous research has demonstrated that inhibiting the Hippo pathway can activate the EGFR signaling pathway, resulting in resistance to EGFR-TKIs. For example, Vichas et al. found that inactivation of Hippo signaling and overexpression of YAP may enhance the oncogenic effects of RIT1. They also found that RIT1 M90I mutation may activate the EGFR/RAS pathway and lead to PC9 cell (EGFR-mutant LUAD cell) resistance to erlotinib or osimertinib [119]. Kurppa et al. showed that YAP activation downregulated the transcription of pro-apoptotic protein BMF by binding to EMT-related transcription factor SLUG, and then induced NSCLC cell dormancy to escape the cytotoxic effects of EGFR/MEK inhibitors. EGFR/MEK inhibitors combined with the covalent TEAD inhibitor MYF-01-37 promoted the apoptosis of dormant tumor cells [120]. In lung cancer cells harboring EGFR-sensitive mutations, YAP activation leads to the upregulation and activation of the tyrosine kinase receptor AXL. AXL activation is associated with drug resistance in lung cancer cells [93, 121]. Moreover, YAP can contribute to resistance to EGFR-TKIs in NSCLC by regulating ROS/HIF-1 α axis and FOXM1 [122, 123]. Furthermore, the YAP/TAZ-TEAD complex can enhance the transcription of genes associated with the EGFR signaling pathway. Several researchers have reported that YAP activation can upregulate the expression of downstream ligands of the EGFR family receptors, including neuregulin 1 (NRG-1), amphiregulin (AREG), and ERBB3/4, through the binding of YAP to TEAD and the formation of an autocrine ring. A positive feedback loop is generated to stabilize Hippo inhibition and enhance MAPK activity, thereby inducing tumor progression and drug resistance [99, 118, 124]. Similarly, blocking the EGFR signaling pathway can lead to the degradation of YAP. Previous studies indicated that inhibiting ERK1/2 reduces the expression level of YAP and subsequently decreases the expression of downstream genes in the Hippo pathway. Inhibition of YAP activity hinders the migration and invasion of NSCLC cells. Meanwhile, forced expression of the ERK2 gene can rescue YAP protein levels [92]. In addition to YAP, TEADs play a crucial role in resistance to EGFR-TKIs. It has been suggested that TEADs are mediators of the EGFR/RAS/RAF/MAPK pathway and play a crucial role in tumor progression and drug resistance in NSCLC with EGFR, KRAS, or BRAF mutation [125]. Therefore, targeting YAP/TEAD is a potential therapeutic approach to overcome acquired resistance to EGFR-TKIs [40, 91, 118, 126].

BRAF V600E mutation

BRAF is a protein kinase that plays a crucial role in cellular signaling. It is a serine–threonine kinase protein with a molecular

weight of 95 kDa. BRAF is located on the long arm of chromosome 7 (7q) [127], and is an important component of the MAP/ERK signaling pathway. Activation of BRAF, a downstream molecule of the receptor tyrosine kinase (RTK), involves RAS-dependent phosphorylation at Ser601 and Thr598 [128]. Upon activation, BRAF can phosphorylate MEK 1/2, which will then phosphorylate ERK1/2 and regulate cell proliferation, division, and apoptosis [127]. The BRAF V600E mutation is detected in ~1–2% of patients diagnosed with lung adenocarcinoma, and targeted therapies against BRAF have shown promising results in treating these patients [129, 130]. Currently, NCCN guidelines have approved dabrafenib, trametinib, and vemurafenib for treating advanced NSCLC with BRAF V600E mutation [130–132]. Previous studies have demonstrated that the increased expression of YAP1 or its analog TAZ significantly diminishes the sensitivity of the lung adenocarcinoma cell line carrying the BRAF V600E mutation (HCC364) to vemurafenib and trametinib. Further mechanistic studies have revealed that YAP can promote the resistance of lung cancer cells to RAF and MEK inhibitors by upregulating the expression of the anti-apoptotic protein BCL-xL. The overexpression of BCL-xL counteracted the impact of YAP1 silencing on the response of HCC364 cells to RAF and MEK inhibitors. Meanwhile, inhibition of YAP or BCL-xL (TW37, ABT-263) synergistically increased the cytotoxic effect of RAF and MEK inhibitors on NSCLC cells [91].

KRAS G12C mutation

KRAS, a membrane protein with intrinsic guanosine triphosphatase (GTPase) activity, is one of the most common oncogenes in humans. Approximately one in seven human cancers and around 25% of human NSCLC cases are characterized by KRAS mutations [133]. The most common mutation site is codon 12 [134]. KRAS G12C mutation can abnormally increase the concentration of GTP-bound KRAS, which overactivates downstream carcinogenic pathways and promotes cell growth [135]. The incidence of KRAS is 14% in lung adenocarcinoma and 0.5–4% in lung squamous carcinoma [136]. Currently, NCCN guidelines have approved Sotorasib [137] and Adagrasib [138] for treating NSCLC patients with KRAS G12C mutations.

Earlier studies have indicated that patients with NSCLC carrying KRAS mutations exhibit elevated levels of YAP expression, and YAP1 silencing can enhance response to trametinib in human lung adenocarcinoma cells (MOR/CPR) encoding KRAS G12C [91]. These findings suggest that increased YAP1 expression may be related to trametinib resistance, which needs further confirmation. Besides, the tumor suppressor RASSF1A can inhibit YAP activity through the GEF-H1/RhoB pathway and promote YAP degradation in the cytoplasm [139]. In NSCLC, the mRNA expression level of RASSF1A was found to be significantly reduced in stage I tumors when compared to normal tissues and was negatively correlated with gene methylation [140]. Moreover, simultaneous RASSF1A methylation and KRAS mutation shortened survival in patients with NSCLC [141], suggesting that RASSF1A methylation may synergistically promote the growth of lung cancer with KRAS mutation by inhibiting the Hippo pathway, which needs further confirmation.

ALK rearrangement

ALK is another potent oncogene in NSCLC. ALK rearrangement is a distinct molecular subtype in NSCLC. It causes an aberrant expression of the tyrosine kinase-containing portion of the ALK gene, resulting in its continuous activation. This fusion event is observed in ~4–6% of individuals with lung adenocarcinoma [142]. Patients with NSCLC who have ALK gene fusion typically are sensitive to ALK-TKIs. Currently, the U.S. Food and Drug Administration (FDA) has approved five ALK-TKIs for the treatment of advanced NSCLC with ALK rearrangement. These approved ALK-TKIs include crizotinib, brigatinib, alectinib, lorlatinib, and ceritinib [143–148]. Although ALK-TKIs have shown significant

benefits in prolonging the overall survival of patients with NSCLC harboring ALK rearrangement, they inevitably lose their efficacy due to drug resistance. To address this issue, ongoing research is focused on understanding the mechanisms of resistance and developing strategies to overcome or prevent it. As previously reported in the literature, resistance to ALK-TKIs can occur through both ALK-dependent mechanisms, such as ALK secondary mutation and ALK gene amplification, as well as ALK-independent mechanisms, including activation of alternative signaling pathways [149, 150]. The emergence of ALK-dependent resistance has led to the advancement of next-generation ALK-TKIs; however, ALK-independent resistance remains a challenge [151].

YAP amplification is an ALK-independent resistance mechanism of ALK-TKIs. Previous studies found that in patients with NSCLC harboring ALK rearrangement, high expression levels of YAP promoted resistance to ALK-TKIs, and the anti-tumor effect of ALK-TKIs was restored after YAP1 knockdown by siRNA *in vivo* and *in vitro* [97]. It has been reported that many genes involved in pathways enriched in cells resistant to crizotinib are related to YAP. Subsequent investigations demonstrated that inhibiting YAP1 genetically or pharmacologically suppressed tumor growth in ALK-TKI-resistant lung adenocarcinoma cells, EML4-ALK transgenic mice, and tumor xenograft models. In contrast, overexpressing YAP reduced the sensitivity of parental cells to ALK-TKIs. In addition, in NSCLC patients harboring ALK fusion, nuclear YAP is highly expressed in ALK-TKI-resistant samples, and high expression levels of YAP are related to weak response to ALK-TKIs [94]. Furthermore, it has been reported that after treating NSCLC cells carrying ALK rearrangement with alectinib *in vivo* and *in vitro*, the YAP1 can be activated, which mediates alectinib resistance by upregulating anti-apoptotic factors Mcl-1 and Bcl-xL [152]. In a separate study, it was discovered that blocking Src homologous phosphotyrosine phosphatase 2 (SHP2) in patient-derived cells (PDCs) resistant to ALK-TKIs reinstated the responsiveness of resistant cells to ALK inhibitors [153]. Interestingly, SHP2 has been found to interact with the YAP/TAZ, which plays a crucial role in the carcinogenic function of SHP2 [154]. Hence, targeting YAP represents a promising therapeutic approach for overcoming acquired resistance to ALK-TKIs.

ROS1 rearrangement

ROS1, a receptor tyrosine kinase with constitutive kinase activity [155], is responsible for encoding both orphan ALK-related receptor tyrosine kinases and members of the insulin receptor family [156]. ROS1 rearrangement causes its components (including the entire tyrosine kinase domain) to fuse with one of the 12 different companion proteins. Common fusion partners include CD74, SLC34A2, CCDC6, and GOPC [157]. The resulting ROS1 fusion kinase is constitutionally active and drives cell transformation. ROS1 fusion is present in various human cancers, including NSCLC [158]. Rearrangement of the ROS1 gene is observed in ~1–2% of patients NSCLC [158–161], particularly in non-smokers, those with lung adenocarcinomas, and patients without alterations in the EGFR or ALK genes [159, 160, 162]. Due to the significant similarity between the kinase domains of ROS1 and ALK, the NCCN guidelines approved ALK inhibitors ceritinib [163], crizotinib [164], entrectinib [165], and lorlatinib [166] for treating NSCLC with ROS1 rearrangement.

Previous study has shown that treatment of lung cancer harboring ROS1 fusion with lorlatinib can activate YAP1 *in vivo* or *in vitro*. YAP1 protects cancer cells against lorlatinib by regulating the AKT signaling pathway. Conversely, YAP1 inhibition by siRNA or a YAP1 inhibitor, verteporfin, enhanced the response to lorlatinib in lung cancer cells (KTOR71). Furthermore, combination therapy with verteporfin and lorlatinib achieved a better anti-tumor effect *in vivo* compared to lorlatinib monotherapy, suggesting that YAP1 may mediate lorlatinib resistance of lung

cancer cells (KTOR71), and simultaneous targeting of YAP1 and ROS1 may represent a more effective treatment strategy for patients with NSCLC harboring ROS1 rearrangement [167].

Role of Hippo pathway in resistance to immunotherapy in NSCLC

Previous studies have demonstrated that essential elements of the Hippo pathway, including MST1/2, LATS1/2, YAP/TAZ, and TEAD, play important roles in innate and adaptive immunity against tumor cells [168–173]. Recently, ICIs have greatly improved the prognosis of some patients with NSCLC. When compared to chemotherapy, ICIs have shown a survival benefit in NSCLC. However, the objective response rate (ORR) in unselected NSCLC patients is only about 20% due to primary resistance to immunotherapy in some patients. In addition, patients who initially respond to immunotherapy may develop resistance over time, known as acquired resistance. Exploring the immunotherapy resistance mechanism is pivotal to enhancing the effectiveness of immunotherapy, expanding its application, and ameliorating ICI resistance [174]. Recent studies on oncogenic signaling pathways that regulate the expression of PD-L1 in tumors have opened up new possibilities for enhancing the effectiveness of immunotherapy and overcoming drug resistance in NSCLC. It was demonstrated that MST1/2 and LATS1/2 inhibit the expression level of PD-L1, while YAP/TAZ promotes PD-L1 expression in lung cancer cell lines [170, 175–177].

Immunohistochemical (IHC) staining of human NSCLC tissues revealed a significant correlation between nuclear YAP expression and PD-L1 expression. Furthermore, YAP inhibition using siRNA, drugs, or genome knockout techniques reduced both the mRNA and protein expression levels of PD-L1 in NSCLC cells [177]. Similarly, another research demonstrated that in NSCLC cells characterized by low levels of YAP and PD-L1 expression, the enforced expression of the YAP gene led to an elevation in PD-L1 protein levels [175]. YAP/TAZ-TEAD increases the activity of PD-L1 promoter, and TAZ-induced upregulation of PD-L1 can inhibit T cell function in human tumor cells. Hence, there is a possibility that YAP/TAZ could increase the expression of PD-L1 in NSCLC cells. Consequently, targeting YAP may enhance the effectiveness of anti-PD-1/PD-L1 monoclonal antibodies in treating advanced NSCLC patients [175–177]. Furthermore, additional studies have found that YAP regulates the expression level of PD-L1 in NSCLC resistant to EGFR-TKIs. Specifically, comparing to the parental PC9 cells (an NSCLC cell line with EGFR 19del mutation), it was observed that both YAP and PD-L1 were upregulated in the cells resistant to gefitinib. In addition, the knockdown of YAP in PC9 cells resistant to gefitinib led to a reduction in PD-L1 expression [176]. The findings presented in the study provide insights into the potential relationship between the EGFR signaling pathway, the Hippo pathway, and the expression of PD-L1 in NSCLC. These results suggest that the expression level of PD-L1 in NSCLC cells could be influenced, at least in part, by EGFR through the Hippo pathway. To explore the potential synergistic effects, it is necessary to investigate the efficacy of the combination of YAP inhibition and anti-PD-L1/PD-1 immune checkpoint inhibitors (ICIs) for NSCLC patients resistant to EGFR-TKIs.

Besides PD-L1, the Hippo pathway also affects other immune checkpoints. For instance, by analyzing the TCGA database, Kim et al. [178] discovered that inhibitory immune checkpoints, such as CTLA-4, PD-1, and PD-L2 were upregulated in the silence of the Hippo pathway (SOH) subgroup in glioblastoma. The authors also conducted IHC staining of YAP and PD-1 in glioblastoma tissue and found nuclear YAP staining showed a strong correlation with PD-1 staining. In addition to impacting on immune checkpoints, the Hippo pathway also affects the tumor immune microenvironment by regulating immune cell function and modulating the expression of cytokines and chemokines [179]. In various tumor types other than lung cancer, the Hippo pathway has been

demonstrated to induce an immunosuppressive microenvironment by regulating M2 polarization of macrophage, Tregs differentiation and stability, B-cell differentiation and development, and the cytotoxicity of CD4+ and CD8+ T cells. This has been discussed in detail elsewhere [179, 180]. Nevertheless, due to the heterogeneity of various cancer types, further studies are needed to measure the effect of the Hippo pathway on the immune microenvironment of NSCLC.

Role of Hippo pathway in resistance to chemoradiotherapy in NSCLC

Due to the limited beneficiaries of targeted therapy and immunotherapy, radiotherapy and chemotherapy still play a crucial role in the treatment of NSCLC patients. Extensive research has demonstrated that the Hippo signaling pathway plays a significant role in acquired chemoradiotherapy resistance in NSCLC. Activation of the YAP/TAZ pathway induces high expression of AXL in mesenchymal lung cancer, leading to doxorubicin resistance [181]. YAP1 expression is significantly elevated in NSCLC cells that are resistant to docetaxel, and the restoration of YAP1 expression can partially alleviate docetaxel resistance [182]. Curcumin has been shown to enhance the sensitivity of NSCLC cells to chemotherapy by facilitating the nucleocytoplasmic translocation and degradation of TAZ [183]. In addition, TEAD2 has the ability to counteract the increased sensitivity of NSCLC cells to cisplatin caused by miR-608 overexpression [184]. These studies collectively suggest the potential involvement of the Hippo pathway in NSCLC chemotherapy resistance. Furthermore, multiple investigations have established the role of the Hippo pathway in radiation resistance. Previous studies indicate that radiation therapy leads to the downregulation of YAP/TAZ, thereby inhibiting tumor proliferation [185]. On the other hand, the activation and nuclear translocation of YAP can reduce the sensitivity of tumors to radiotherapy [186, 187].

Potential drugs for targeting the Hippo pathway

The YAP/TAZ-TEAD can activate the transcription of downstream genes in tumor cells, thereby maintaining tumor cell stemness and promoting the survival, proliferation, EMT, metastasis, and drug resistance of tumor cells [17, 19]. Currently, various drugs have been applied to target the Hippo pathway in different cancer types, which have been summarized in other reviews [67, 188]. Here, we focused on drugs targeting the Hippo pathway in NSCLC (Tables 1 and 2).

Targeting YAP/TAZ

YAP and TAZ are the core effectors of the Hippo pathway. They are negatively regulated by upstream components of the Hippo pathway, such as NF2, MST1/2, and LATS1/2 [17]. Currently, several *in vitro* and *in vivo* studies have confirmed the role of YAP and TAZ in promoting tumor cell proliferation, metastasis, and resistance to drugs [67]. In NSCLC, YAP1 is significantly upregulated and plays an oncogenic role compared to paracarcinoma normal tissues [189]. Huang et al. found that in lung squamous cell carcinoma cells, small-molecule digitoxin can downregulate YAP phosphorylation and activate YAP and nuclear sequestration. Activated YAP can lead to reactive oxygen species (ROS) accumulation by downregulating the antioxidant enzyme GPX2 and suppressing tumor progression. In patient-derived xenograft models, digitalis effectively inhibited lung squamous cell carcinoma progression and reduced YAP expression [190]. Therefore, targeting YAP has anti-tumor effects on human NSCLC *in vitro* and *in vivo*.

Targeting YAP/TAZ-TEAD interactions

YAP and TAZ contain the N-terminal TEAD binding domain (TBD), which is a spherical structure that binds to TEAD and interacts at three different interfaces [191]. Verteporfin is a benzoporphyrin

Table 1. Preclinical studies of drugs targeting the Hippo pathway.

Drug/small molecular	Mechanism	Model	Result	Reference
Digitoxin	YAP	Lung squamous cell lines (HTB-182, L78, CRL-5889); patient-derived xenograft (PDX)	Digitoxin effectively inhibited lung SCC progression by attenuating YAP phosphorylation and promoting YAP nuclear sequestration.	[190]
Verteporfin	YAP-TEAD	NSCLC cell lines (H1975)	Verteporfin, in combination with erlotinib, synergistically reduced migration, invasion, and tumor sphere formation abilities.	[99]
Verteporfin	YAP-TEAD	NSCLC cell lines (A549, H460)	Verteporfin inhibited the metastasis of A549 and H460 cells and the expression of EMT-related markers.	[189]
XAV939 MYF-01-37	YAP-TEAD	NSCLC cell lines (PC9, HCC827, HCC4006, HCC2279, H1975, H3122, EBC-1)	XAV939 or MYF-01-37 can deplete dormant cells by enhancing apoptosis induced by EGFR/MEK inhibition.	[119]
IK-930	TEAD palmitoylation	NSCLC cell lines (A549(KRAS G12S); H1975(EGFR))	IK-930 in combination with EGFR or MEK inhibitors can enhance cell apoptosis and anti-tumor activity.	[63]
VT3989	TEAD palmitoylation	NSCLC cell lines (H1975, HCC827) ; CDX, PDX	VT3989, in combination with osimertinib, synergistically exerted anti-tumor effects.	[201]
VT104	TEAD palmitoylation	NSCLC CDX, PDX	VT104, in combination with osimertinib, induced a synergistic anti-tumor response.	[204]
MGH-CP1	TEAD palmitoylation	Various cells; including NSCLC cell lines (NCI-H226, NCI-H1299)	MGH-CP1 sensitivity is related to the YAP dependence.	[205]

NSCLC non-small cell lung cancer, YAP Yes-associated protein, TEAD transcriptional-enhanced associate domain, CDX cell line-derived xenograft, PDX patient-derived xenograft, SCC squamous cell carcinoma, EMT epithelial-mesenchymal transition, EGFR epidermal growth factor receptor, MEK mitogen-activated protein kinase kinases.

Table 2. Clinical studies of drugs targeting the Hippo pathway.

Agents	Mechanism	Clinical trial	Phase	Patients (including lung cancer)	Status
IAG933	YAP-TEAD	NCT04857372	I	Advanced malignant mesothelioma; solid tumors with NF2/LATS1/LATS2 gene alterations (truncated mutations or gene deletions) or functional YAP/TAZ fusions.	Recruiting
IK-930	TEAD palmitoylation	NCT05228015	I	Malignant mesothelioma with NF2 deletion; epithelioid hemangioendothelioma with TAZ-CAMTA1 or YAP1-TFE3 gene fusion; solid tumors with NF2 deletion or YAP1/TAZ fusion gene	Recruiting
BPI-460372888	TEAD palmitoylation	NCT05789602	I	Malignant mesothelioma; epithelioid hemangioendothelioma; solid tumors with NF2 deletion, YAP/TAZ fusion, LATS1/2 mutation, or other Hippo pathway dysregulation.	Recruiting
VT3989	TEAD palmitoylation	NCT04665206	I	Patients with mesothelioma with or without NF2 mutations who have progressed after standard treatment; refractory locally advanced or metastatic solid tumors with NF2 mutations.	Recruiting

NF2 neurofibromin 2, LATS large tumor suppressor kinase, YAP Yes-associated protein, TAZ transcriptional co-activator PDZ-binding motif, TEAD transcriptional-enhanced associate domain.

derivative, which is currently used for treating ocular vascular diseases [192, 193]. YAP1 expression is significantly upregulated in NSCLC. The binding of YAP-TEAD has been shown to enhance EMT, proliferation, invasion, and migration of lung cancer cells. Verteporfin exerts an anti-tumor effect on NSCLC by blocking AP-TEAD complex formation in vitro [189]. In human NSCLC cells, it was observed that the overexpression of YAP led to the development of resistance to erlotinib, a targeted therapy drug. Conversely, the sensitivity of H1975 cells (an NSCLC cell line with EGFR L858R/T790M mutation) to erlotinib was enhanced by inhibiting YAP through the use of small interfering RNA (siRNA) or verteporfin. In addition, the combination of verteporfin and erlotinib can synergistically inhibit H1975 cell migration, invasion, and tumor globular formation [99]. YAP-TEAD inhibited the proapoptotic factor BMF through the EMT transcription factor SLUG, thereby preventing apoptosis [120]. In NSCLC with EGFR mutations, inhibition of EGFR/MEK led to dormant cell formation that exhibited increased YAP-TEAD activity. In addition, YAP-TEAD inhibitors, XAV939 and MYF-01-37, enhanced EGFR/MEK inhibitor-induced apoptosis, playing a synergistic role in tumor [120].

Targeting TEAD palmitoylation

In tumors induced by Hippo pathway dysregulation, YAP and TAZ do not possess an intrinsic DNA binding domain and need to bind to TEAD to activate downstream oncogenes [74]. Therefore, TEAD is also an important drug target. TEAD is an evolutionarily conserved transcription factor that can undergo auto-palmitoylation at a conserved cysteine residue site. Post-translational modification of this protein is crucial for effective transcription, protein stability, and YAP/TAZ-TEAD interaction [52, 79, 194, 195]. The palmitate component of TEAD is deeply embedded within a hydrophobic pocket, and this unique biochemical and structural characteristic makes small molecules ideal inhibitors of TEAD. Therefore, various TEAD inhibitors have been developed for targeting the conserved palmitoylation sites and inhibiting the transcription of downstream target genes [196–200]. The potential anti-cancer role of TEAD palmitoylation has been demonstrated in NF2-deficient malignant mesothelioma [63, 199, 201].

It has been reported that VT3989 combined with osimertinib has strong synergistic anti-tumor effects against several EGFR-mutated NSCLC cell lines. In addition, VT3989 and osimertinib synergistically exerted anti-tumor effects in xenograft models of NCI-H1975 and HCC827 cell lines. Furthermore, when compared to the use of osimertinib alone, the combination of VT3989 and osimertinib has shown enhanced efficacy and delayed tumor regeneration. Moreover, in comparison to osimertinib monotherapy, the combination of VT3989 and osimertinib enhanced the effectiveness of osimertinib and delayed tumor regeneration [201]. A recently published phase I trial showed that VT3989 was safe and well-tolerated, with durable anti-tumor activity [202, 203]. IK-930 is a specific small-molecule inhibitor that selectively targets the palmitoylation of TEAD. In tumors with EGFR or KRAS mutation, IK-930, in combination with EGFR or MEK inhibitors, enhanced cell apoptosis and anti-tumor activity in vivo. In NSCLC cell line (A549) with KRAS G12S mutation, the combination of mitogen-activated protein kinase (MEK) inhibitor trametinib and IK-930 exerted a synergistic anti-tumor effect. Furthermore, in the xenograft model of the H1975 NSCLC cell line, the combination of IK-930, osimertinib, and trametinib led to the complete regression of the tumors. In addition, in the xenograft model of H1975 NSCLC cell line, the combination of osimertinib, trametinib, and IK-930 led to complete regression of the tumor [63]. In both NSCLC PDX and CDX models, the combination of osimertinib and VT104, a TEAD inhibitor, exhibited a synergistic anti-tumor response [204]. Furthermore, Sun et al. reported that the TEAD palmitoylation inhibitor, MGH-CP1, combined with its analogs, inhibited the stem-like properties of cancer cells, prevented excessive tumor

growth, and suppressed tumorigenesis both in vitro and in vivo [205]. The sensitivity to MGH-CP1 is significantly correlated with YAP dependence in various tumor cell lines, including NSCLC. These studies indicated that TEAD palmitoylation inhibitors combined with inhibitors of other oncogenic factors can synergistically kill tumors in NSCLC, suggesting the potential role of TEAD inhibitors in treating drug-resistant NSCLC.

Potential biomarkers that may benefit from drugs targeting the Hippo pathway

How to screen patients who can potentially benefit from drugs targeting the Hippo pathway remains to be known. Table 3 shows candidate biomarkers targeting the Hippo pathway. Genetic alterations affecting the Hippo pathway in NSCLC have been identified. For example, pan-cancer analysis of TEADs showed that approximately 5% of cancers exhibit amplification of TEAD copy numbers. For instance, lung squamous cell carcinoma carries TEAD2, TEAD3, and TEAD4 amplification, and lung adenocarcinoma carries TEAD3 amplification [83]. In pancreatic ductal carcinoma and breast cancer, the overexpression of TEAD or nuclear accumulation is related to poor survival [87, 89]. Additional research is required to determine the predictive significance of TEAD in lung cancer. However, in addition to TEAD, the expression of YAP/TAZ should also be taken into consideration. YAP and TAZ frequently exhibit amplification or overactivation in various human cancers, including lung cancer [25, 26]. Earlier studies have indicated that the amplification of YAP1 and WWTR1, which encode YAP and TAZ, respectively, has been observed in 16% of lung squamous cell carcinoma [206]. In addition, studies have reported a significant correlation between sensitivity to TEAD palmitoylation inhibitor, MGH-CP1, and YAP dependence in NSCLC [205]. Hence, the amplification of YAP could serve as a potential biomarker for predicting the efficacy of TEAD inhibitors in NSCLC. TAZ-CAMTA1 fusion in epithelioid hemangioendothelioma (EHE) [207, 208], and NF2 deletion in MPM [57] can also predict response to TEAD inhibitors; however, these genetic alterations are extremely rare in lung cancer [57]. In addition, mutations and deletions of SAV1 and LATS1/2 are also associated with the proliferation of various tumors [61, 62, 209], and their predictive role in lung cancer needs further studies. Although genetic alterations in the key components of the Hippo pathway are uncommon in lung cancer, the significant relationship between genetic alterations and the efficacy of targeted therapy for Hippo pathway indicates that techniques for detecting these genetic alterations, such as the next-generation sequencing (NGS) technology, may help identify potential candidates who will obtain the utmost benefit. Furthermore, NGS may reveal additional pathogenic genetic changes.

Due to the limited occurrence of genetic alterations affecting different elements of the Hippo pathway in lung cancer, a more practical approach for stratifying tumors could be based on protein expression. Using immunohistochemical (IHC) techniques, Drexler et al. [210]. evaluated the protein levels of different constituents of the Hippo pathway in 103 patients with pancreatic ductal carcinoma. The results showed that the Hippo pathway was activated in non-metastatic lesions, and the expression of MST1, MST2, pLATS, pYAP, and 14-3-3 was significantly upregulated ($P < 0.01$). In the metastatic lesions of the liver, the Hippo pathway was inhibited, and LATS1, LATS2, YAP, TEAD2, and TEAD3 were significantly upregulated ($P < 0.01$), and high pYAP expression was associated with better OS and DFS. Tang et al. [88]. observed that the protein levels of TEAD4 were markedly increased in the colorectal adenoma (CRA) tissues. Furthermore, patients who exhibited elevated TEAD4 expression in the normal colon mucosa had an increased risk of relapse following polypectomy. In addition, the study demonstrated that inhibiting TEAD4 expression effectively suppressed the proliferation of colorectal cancer cells in vitro and inhibited tumor growth in vivo. In mouse models

Table 3. Potential Biomarkers targeting the Hippo pathway.

Biomarker	Type	Model	Test method	Result	Reference
NF2	Fusion	451 LUAD, 251 LUSC, 9 LCLC, 11 LACC and 24 NSCLC cell lines	RNAseq	NF2-OSBP2 (LUSC) and NF2-MORC2 (LUSC) fusions led to loss of function of NF2.	[48]
	Mutations	Common solid cancers and acute leukemia, including 45 NSCLC (24 LUAD, 21 LUSC)	SSCP assay	NF2 exon 13 c.1351 G > A was found in one LUSC (1/45; 2.2%).	[52]
LATS1/2	Fusion	451 LUAD, 251 LUSC, 9 LCLC, 11 LACC and 24 NSCLC cell lines	RNAseq	LATS1-LACE1 fusion in LUSC and PCMT1-LATS1 fusion in LUAD) impair their cancer inhibition function.	[49]
	Mutation	51 LUAD, 67 LUSC, 11 LCLC, and 13 lung cancer cell lines	DHPLC detection	Nine different genetic alterations were detected in LATS2, mostly occurring in advanced LUSC.	[46]
	mRNA levels	40 LUAD, 38 LUSC, 6 LCLC and adjacent healthy tissue	qRT-PCR	mRNA expression of LATS2 decreased in all tumors, especially in LCLC.	[46]
YAP	Fusion	451 LUAD, 251 LUSC, 9 LCLC, 11 LACC and 24 NSCLC cell lines	RNAseq	YAP1-BIRC2 fusion in LUSC, and YAP1-ENSG0000254968 fusion in LUAD retained the tumor-promoting function of YAP.	[49]
	mRNA levels	9,125 tumor samples across 33 cancer types from TCGA, including LUAD and LUSC.	TCGA database	The combined amplification frequency of YAP1 and TAZ ranged from 0% to 19%, with LUSC ranking second and LUAD eighth among 33 cancer types.	[26]
	mRNA levels	Four human lung tumor tissues and adjacent normal lung tissues	RT-PCR	mRNA levels of YAP were higher in tumor tissues compared with their adjacent normal tissues.	[56]
	Protein levels	66 LUAD and 102 squamous cell carcinomas	IHC	In adenocarcinoma, the expression of cyclin A was independently correlated with the nuclear expression of YAP. Nuclear expression of YAP was an important predictor of EGFR gene amplification. YAP expression in the cytoplasm was an independent predictor of low pTNM stage (stage I) in LUSC.	[47]
	Protein levels	10 human LUAD tissues	IHC	YAP and downstream targets were associated with a worse prognosis.	[50]
	Protein levels	Four human lung tumor tissues and adjacent normal lung tissues	Immunoblotting, Immunofluorescent staining	Total YAP protein levels and nuclear YAP levels were significantly increased in lung cancer tissue, while cytoplasmic levels of pYAP were higher in adjacent normal lung tissues.	[56]
TAZ	mRNA levels	TMA encompassing 196 NSCLC cases	WGS	Higher mRNA levels of TAZ were associated with poor survival.	[48]
	Fusion	451 LUAD, 251 LUSC, 9 LCLC, 11 LACC and 24 NSCLC cell lines	RNAseq	WWTR1-SLC9A9 fusion in LUAD retained the tumor-promoting function of TAZ.	[49]
	Protein levels	10 human LUAD tissues	IHC	TAZ and downstream targets were associated with a negative prognosis.	[50]
	Protein levels	TMA encompassing 345 NSCLC cases	IHC	Higher protein levels of TAZ were associated with poor survival.	[48]
TEAD	mRNA levels	TCGA database: 32 tumor types, including 515 LUAD and 498 LUSC	TCGA database	TEAD2, TEAD3, and TEAD4 were overexpressed in LUSC; TEAD3 was overexpressed in LUAD.	[83]

NSCLC non-small cell lung cancer, LUAD lung adenocarcinoma, LUSC squamous cell carcinoma, LCLC large cell lung cancer, LACC large cell lung cancer, SSCP single-strand conformation polymorphism assay, pTNM pathologic TNM, TCGA The Cancer Genome Atlas, TMA tissue microarray, IHC immunohistochemistry, RT-PCR Reverse Transcription-Polymerase Chain Reaction, WGS whole-exome sequencing, RNAseq RNA sequencing, DHPLC denaturing high-performance liquid chromatography, NF2 neurofibromin 2, LATS large tumor suppressor kinase, YAP Yes-associated protein, TAZ transcriptional co-activator PDZ-binding motif, TEAD transcriptional-enhanced associate domain, EGFR epidermal growth factor receptor.

of 4NQO-induced HNSCC, it was observed that higher levels of TEAD4 immunostaining were correlated with the progression of the disease. The protein abundance of TEAD4 in IHC staining exhibited a substantial increase in HNSCC clinical specimens compared to control tissues [90]. The aforementioned studies indicate that the protein expression levels of components within the Hippo pathway could function as a candidate biomarker for identifying suitable patients and predicting the effectiveness of drugs targeting this pathway.

Future outlook

This review offers a thorough overview of the involvement of the Hippo pathway and its downstream molecules, namely YAP/TAZ and TEAD, in the progression and drug resistance of NSCLC. There are still some urgent issues that need to be addressed. First, the Hippo pathway can interact with various carcinogenic signaling pathways, affecting the development and drug resistance of NSCLC. However, it is currently unclear how the Hippo pathway interacts with different signaling pathways and the precise mechanisms underlying the crosstalk between the Hippo pathway and various signaling pathways in NSCLC to produce a coordinated tumor-promoting effect. Second, due to the rarity of genetic alterations affecting different elements of the Hippo pathway in NSCLC, it is crucial to screen candidate patients who may benefit from drugs targeting this pathway. The protein expression of YAP/TAZ and TEAD may be a new target for future research. Third, the development of drugs that target the Hippo pathway represents a promising approach to treat NSCLC and overcome drug resistance. However, further studies are needed on the timing, mode, and sequence of drug use. Fourth, there are other novel therapeutic strategies except for traditional chemotherapy, immunotherapy, and small-molecule inhibitors. CRISPR/Cas9 is an efficient gene editing tool that can precisely excise target sites in the genome by editing the nucleotide sequence of a single guide RNA (sgRNA), correcting pathogenic mutations, or silencing genes associated with disease onset [211, 212]. Its efficacy has been demonstrated for diagnosing and treating various cancers, including lung cancer [213]. Proteolysis targeting chimera (PROTAC) technology selectively degrades disease-related target proteins, providing significant advantages in overcoming drug resistance due to gene mutations or overexpression. It also has the potential to target proteins that are traditionally considered undruggable. Currently, clinical research is underway for PROTAC molecules targeting a range of diseases, including cancer [214]. Exploring the potential use of targeted protein degradation systems, such as PROTAC and CRISPR systems, in targeting the Hippo pathway is also a future research direction. Fifth, although several studies have explored the involvement of the Hippo pathway in NSCLC, YAP, and TAZ have been found to exhibit suppressive effects in neuroendocrine and hematological tumors [215]. Hence, more data are required to fully understand the clinical effectiveness and potential toxicity of targeted therapy for the Hippo pathway in NSCLC. Sixth, due to the interactions between the Hippo pathway and other carcinogenic pathways, investigating the mechanisms of resistance to drugs targeting the Hippo pathway represents a crucial area for future research.

REFERENCES

- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72:7–33.
- McIntyre A, Ganti AK. Lung cancer—a global perspective. *J Surg Oncol.* 2017;115:550–4.
- Cao M, Chen W. Epidemiology of lung cancer in China. *Thorac Cancer.* 2019;10:3–7.
- Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of Patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. *J Am Med Assoc.* 2019;321:1391–9.
- Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022. NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2022;20:497–530.
- Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update. *J Clin Oncol.* 2021;39:1040–91.
- Nguyen CDK, Yi C. YAP/TAZ signaling and resistance to cancer therapy. *Trends Cancer.* 2019;5:283–96.
- Ma S, Meng Z, Chen R, Guan KL. The Hippo pathway: biology and pathophysiology. *Annu Rev Biochem.* 2019;88:577–604.
- Wang M, Dai M, Wang D, Xiong W, Zeng Z, Guo C. The regulatory networks of the Hippo signaling pathway in cancer development. *J Cancer.* 2021;12:6216–30.
- Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. *Cell.* 2015;163:811–28.
- Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. *Genes Dev.* 2016;30:1–17.
- Rausch V, Hansen CG. The Hippo pathway, YAP/TAZ, and the plasma membrane. *Trends Cell Biol.* 2020;30:32–48.
- Dupont S. Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. *Exp Cell Res.* 2016;343:42–53.
- Mohri Z, Del Rio Hernandez A, Krams R. The emerging role of YAP/TAZ in mechanotransduction. *J Thorac Dis.* 2017;9:E507–9.
- Park J, Hansen CG. Cellular feedback dynamics and multilevel regulation driven by the hippo pathway. *Biochem Soc Trans.* 2021;49:1515–27.
- Hergovich A, Hemmings BA. Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling. *BioFactors.* 2009;35:338–45.
- Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. *Nat Rev Cancer.* 2015;15:73–9.
- Wang S, Zhou L, Ling L, Meng X, Chu F, Zhang S, et al. The crosstalk between Hippo-YAP Pathway and innate immunity. *Front Immunol.* 2020;11:323.
- Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. *Nat Rev Drug Discov.* 2014;13:63–79.
- Song Y, Fu J, Zhou M, Xiao L, Feng X, Chen H, et al. Activated Hippo/Yes-associated protein pathway promotes cell proliferation and anti-apoptosis in endometrial stromal cells of endometriosis. *J Clin Endocrinol Metab.* 2016;101:1552–61.
- Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. *Development.* 2014;141:1614–26.
- Davis JR, Tapon N. Hippo signalling during development. *Development* 2019;146:dev167106.
- Pan D. The hippo signaling pathway in development and cancer. *Dev Cell.* 2010;19:491–505.
- Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. *Genes Dev.* 2012;26:1300–5.
- Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. *Cancer Cell.* 2016;29:783–803.
- Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, et al. Comprehensive molecular characterization of the Hippo signaling pathway in cancer. *Cell Rep.* 2018;25:1304–17.e1305.
- Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, et al. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellular carcinoma. *Oncol Rep.* 2013;29:840–6.
- Chen J, Zhang K, Zhi Y, Wu Y, Chen B, Bai J, et al. Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. *Clin Transl Med.* 2021;11:e478.
- Liu Y, Song Y, Cao M, Fan W, Cui Y, Cui Y, et al. A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma. *Clin Transl Med.* 2022;12:e836.
- Ma S, Wu Z, Yang F, Zhang J, Johnson RL, Rosenfeld MG, et al. Hippo signalling maintains ER expression and ER(+) breast cancer growth. *Nature.* 2021;591:E1–10.
- Dai Y, Liu S, Zhang WQ, Yang YL, Hang P, Wang H, et al. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. *Oncotarget.* 2017;8:4096–109.
- Zhang Y, Yan S, Chen J, Gan C, Chen D, Li Y, et al. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma. *J Cell Mol Med.* 2017;21:3718–29.
- Zhang WQ, Dai YY, Hsu PC, Wang H, Cheng L, Yang YL, et al. Targeting YAP in malignant pleural mesothelioma. *J Cell Mol Med.* 2017;21:2663–76.
- Xia J, Zeng M, Zhu H, Chen X, Weng Z, Li S. Emerging role of Hippo signalling pathway in bladder cancer. *J Cell Mol Med.* 2018;22:4–15.

35. Kulkarni A, Chang MT, Vissers JHA, Dey A, Harvey KF. The Hippo pathway as a driver of select human cancers. *Trends Cancer*. 2020;6:781–96.
36. Chen L, Feng P, Peng A, Qiu X, Zhu X, He S, et al. cAMP response element-binding protein and Yes-associated protein form a feedback loop that promotes neurite outgrowth. *J Cell Mol Med*. 2018;22:374–81.
37. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. *Cell*. 2014;158:171–84.
38. Song J, Xie LX, Zhang XY, Hu P, Long MF, Xiong F, et al. Role of YAP in lung cancer resistance to cisplatin. *Oncol Lett*. 2018;16:3949–54.
39. Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. *Cell Cycle*. 2015;14:1765–6.
40. McGowan M, Kleinberg L, Halvorsen AR, Helland A, Brustugun OT. NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors. *Genes Cancer*. 2017;8:497–504.
41. Dubois F, Keller M, Calvayrac O, Soncin F, Hoa L, Hergovich A, et al. RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway. *Cancer Res*. 2016;76:1627–40.
42. Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, et al. Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. *Oncol Rep*. 2019;42:697–707.
43. Ye XY, Luo QQ, Xu YH, Tang NW, Niu XM, Li ZM, et al. 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway. *J Cell Mol Med*. 2015;19:651–63.
44. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of Yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. *Cancer Sci*. 2010;101:1279–85.
45. Thompson BJ. YAP/TAZ: drivers of tumor growth, metastasis, and resistance to therapy. *Bioessays*. 2020;42:e1900162.
46. Strazisar M, Mlakar V, Glavac D. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. *Lung Cancer*. 2009;64:257–62.
47. Kim JM, Kang DW, Long LZ, Huang SM, Yeo MK, Yi ES, et al. Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma. *Hum Pathol*. 2011;42:315–23.
48. Noguchi S, Saito A, Horie M, Mikami Y, Suzuki HI, Morishita Y, et al. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. *Clin Cancer Res*. 2014;20:4660–72.
49. Dhanasekaran SM, Balbin OA, Chen G, Nadal E, Kalyana-Sundaram S, Pan J, et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. *Nat Commun*. 2014;5:5893.
50. Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. *Oncogene*. 2017;36:4573–84.
51. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. *Cell*. 2013;154:1342–55.
52. Kim NG, Gumbiner BM. Cell contact and NF2/Merlin-dependent regulation of TEAD palmitoylation and activity. *Proc Natl Acad Sci USA*. 2019;116:9877–82.
53. White SM, Avantaggiati ML, Nemazany I, Di Poto C, Yang Y, Pende M, et al. YAP/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells. *Dev Cell*. 2019;49:425–43.e429.
54. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. *Nat Rev Cancer*. 2013;13:246–57.
55. Zhang N, Zhao Z, Long J, Li H, Zhang B, Chen G, et al. Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Oncol Rep*. 2017;38:3650–8.
56. Kaneda A, Seike T, Danjo T, Nakajima T, Otsubo N, Yamaguchi D, et al. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma. *Am J Cancer Res*. 2020;10:4399–415.
57. Yoo NJ, Park SW, Lee SH. Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias. *Pathology*. 2012;44:29–32.
58. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). *Genes Dev*. 2010;24:72–85.
59. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. *Cancer Cell*. 2009;16:425–38.
60. Malik SA, Khan MS, Dar M, Hussain MU, Shah MA, Shafi SM, et al. Molecular alterations and expression dynamics of LATS1 and LATS2 genes in non-small-cell lung carcinoma. *Pathol Oncol Res*. 2018;24:207–14.
61. He Z, Li R, Jiang H. Mutations and copy number abnormalities of Hippo pathway components in human cancers. *Front Cell Dev Biol*. 2021;9:661718.
62. Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. *Cell Death Differ*. 2017;24:1488–501.
63. Amidon BS, Sanchez-Martin M, Bartolini W, Syed S, McGovern K, Xu L, et al. Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway. *Cancer Res*. 2022;82:2156.
64. Bhat KP, Salazar KL, Balasubramanian V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. *Genes Dev*. 2011;25:2594–609.
65. Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang W, et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. *Mol Oncol*. 2015;9:1091–105.
66. Cordenonsi M, Zanconato F, Azolin L, Forcato M, Rosato A, Frasson C, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. *Cell*. 2011;147:759–72.
67. Franklin JM, Wu Z, Guan KL. Insights into recent findings and clinical application of YAP and TAZ in cancer. *Nat Rev Cancer*. 2023;23:512–25.
68. Zhang W, Gao Y, Li F, Tong X, Ren Y, Han X, et al. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin. *Cancer Res*. 2015;75:4450–7.
69. Garcia K, Gingras AC, Harvey KF, Tanas MR. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities. *Trends Cancer*. 2022;8:1033–45.
70. Wang P, Gong Y, Guo T, Li M, Fang L, Yin S, et al. Activation of aurora A kinase increases YAP stability via blockage of autophagy. *Cell Death Dis*. 2019;10:432.
71. Seo J, Kim MH, Hong H, Cho H, Park S, Kim SK, et al. MK5 regulates YAP stability and is a molecular target in YAP-driven cancers. *Cancer Res*. 2019;79:6139–52.
72. Lim SK, Lu SY, Kang SA, Tan HJ, Li Z, Adrian Wee ZN, et al. Wnt signaling promotes breast cancer by blocking ITCH-mediated degradation of YAP/TAZ transcriptional coactivator WBP2. *Cancer Res*. 2016;76:6278–89.
73. Guo J, Wu Y, Yang L, Du J, Gong K, Chen W, et al. Repression of YAP by NCTD disrupts NSCLC progression. *Oncotarget*. 2017;8:2307–19.
74. Totaro A, Panciera T, Piccolo S. YAP/TAZ upstream signals and downstream responses. *Nat Cell Biol*. 2018;20:888–99.
75. Ota M, Sasaki H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. *Development*. 2008;135:4059–69.
76. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev*. 2007;21:2747–61.
77. Xiao JH, Davidson I, Matthes H, Garnier JM, Chambon P. Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1. *Cell*. 1991;65:551–68.
78. Lin KC, Moroishi T, Meng Z, Jeong HS, Plouffe SW, Sekido Y, et al. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. *Nat Cell Biol*. 2017;19:996–1002.
79. Chan P, Han X, Zheng B, DeRan M, Yu J, Jarugumilli GK, et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. *Nat Chem Biol*. 2016;12:282–9.
80. Park JH, Shin JE, Park HW. The role of Hippo pathway in cancer stem cell biology. *Mol Cells*. 2018;41:83–92.
81. Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. *Nat Rev Mol Cell Biol*. 2019;20:211–26.
82. Kim CL, Choi SH, Mo JS. Role of the Hippo pathway in fibrosis and cancer. *Cells*. 2019;8:468.
83. Li F, Feng Y, Jiang Q, Zhang J, Wu F, Li Q, et al. Pan-cancer analysis, cell and animal experiments revealing TEAD4 as a tumor promoter in ccRCC. *Life Sci*. 2022;293:120327.
84. Zhang J, Liu P, Tao J, Wang P, Zhang Y, Song X, et al. TEA domain transcription factor 4 is the major mediator of Yes-associated protein oncogenic activity in mouse and human hepatoblastoma. *Am J Pathol*. 2019;189:1077–90.
85. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. *J Biol Chem*. 2009;284:14347–58.
86. Diepenbruck M, Waldmeier I, Ivanek R, Berninger P, Arnold P, van Nimwegen E, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition. *J Cell Sci*. 2014;127:1523–36.
87. He L, Yuan L, Sun Y, Wang P, Zhang H, Feng X, et al. Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression. *Cancer Res*. 2019;79:4399–411.
88. Tang JY, Yu CY, Bao YJ, Chen L, Chen J, Yang SL, et al. TEAD4 promotes colorectal tumorigenesis via transcriptionally targeting YAP1. *Cell Cycle*. 2018;17:102–9.
89. Drexler R, Fahy R, Kuchler M, Wagner KC, Reese T, Ehmke M, et al. Association of subcellular localization of TEAD transcription factors with outcome and progression in pancreatic ductal adenocarcinoma. *Pancreatol*. 2021;21:170–9.

90. Zhang W, Li J, Wu Y, Ge H, Song Y, Wang D, et al. TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma. *Cancer Cell Int*. 2018;18:178.
91. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. *Nat Genet*. 2015;47:250–6.
92. You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, et al. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. *Oncotarget*. 2015;6:4357–68.
93. Ghiso E, Migliore C, Ciciriello V, Morando E, Petrelli A, Corso S, et al. YAP-dependent AXL overexpression mediates resistance to EGFR inhibitors in NSCLC. *Neoplasia*. 2017;19:1012–21.
94. Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, et al. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. *EMBO Mol Med*. 2019;11:e10581.
95. Isago H, Mitani A, Mikami Y, Horie M, Urushiyama H, Hamamoto R, et al. Epithelial expression of YAP and TAZ is sequentially required in lung development. *Am J Respir Cell Mol Biol*. 2020;62:256–66.
96. Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. *Clin Cancer Res*. 2015;21:2580–90.
97. Sato H, Kubota D, Qiao H, Jungbluth A, Rekhman N, Schoenfeld AJ, et al. SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor inhibitors. *JCO Precis Oncol*. 2022;6:e2200088.
98. Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, et al. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer. *Cancer Sci*. 2023;114:546–60.
99. Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z, et al. YAP promotes erlotinib resistance in human non-small cell lung cancer cells. *Oncotarget*. 2016;7:51922–33.
100. Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, et al. Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC. *J Natl Cancer Inst*. 2017;109:djx014.
101. Kitano H, Chung JY, Ylaya K, Conway C, Takikita M, Fukuoka J, et al. Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. *J Histochem Cytochem*. 2014;62:335–46.
102. Hu C, Zhou H, Liu Y, Huang J, Liu W, Zhang Q, et al. ROCK1 promotes migration and invasion of non-small-cell lung cancer cells through the PTEN/PI3K/FAK pathway. *Int J Oncol*. 2019;55:833–44.
103. Lu M, Liu B, Xiong H, Wu F, Hu C, Liu P. Trans-3,5,4-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498. *J Cell Mol Med*. 2019;23:2431–41.
104. Liu W, Liang Y, Chan Q, Jiang L, Dong J. CX3CL1 promotes lung cancer cell migration and invasion via the Src/focal adhesion kinase signaling pathway. *Oncol Rep*. 2019;41:1911–7.
105. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. *Annu Rev Pathol*. 2011;6:49–69.
106. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *New Engl J Med*. 2004;350:2129–39.
107. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004;304:1497–1500.
108. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci USA*. 2004;101:13306–11.
109. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer*. 2007;7:169–81.
110. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *New Engl J Med*. 2009;361:947–57.
111. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol*. 2010;11:121–8.
112. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *New Engl J Med*. 2010;362:2380–8.
113. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). *Ann Oncol*. 2015;26:1877–83.
114. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *New Engl J Med*. 2018;378:113–25.
115. Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. *J Clin Oncol*. 2018;36:2244–50.
116. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017;18:1454–66.
117. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012;13:239–46.
118. Huang JM, Nagatomo I, Suzuki E, Mizuno T, Kumagai T, Berezov A, et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. *Oncogene*. 2013;32:2220–9.
119. Vichas A, Riley AK, Nkisi NT, Kamlapurkar S, Parrish PCR, Lo A, et al. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. *Nat Commun*. 2021;12:4789.
120. Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. *Cancer Cell*. 2020;37:104–22.e112.
121. Lee JE, Park HS, Lee D, Yoo G, Kim T, Jeon H, et al. Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. *Biochem Biophys Res Commun*. 2016;474:154–60.
122. Tung JN, Lin PL, Wang YC, Wu DW, Chen CY, Lee H. PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression. *Oncotarget*. 2018;9:4637–46.
123. Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al. A YAP/FOXO1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. *Sci Transl Med*. 2020;12:eaa24589.
124. Sudol M. Neuregulin 1-activated ERBB4 as a “dedicated” receptor for the Hippo-YAP pathway. *Sci Signal*. 2014;7:pe29.
125. Huh HD, Kim DH, Jeong HS, Park HW. Regulation of TEAD transcription factors in cancer biology. *Cells*. 2019;8:600.
126. Lee TF, Tseng YC, Nguyen PA, Li YC, Ho CC, Wu CW. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. *Sci Rep*. 2018;8:271.
127. Zaman A, Wu W, Bivona TG. Targeting oncogenic BRAF: past, present, and future. *Cancers*. 2019;11:1197.
128. Zhang BH, Guan KL. Regulation of the Raf kinase by phosphorylation. *Exp Lung Res*. 2001;27:269–95.
129. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. *Nature*. 2002;417:949–54.
130. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland A, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*. 2017;18:1307–16.
131. Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM, et al. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. *J Thorac Oncol*. 2022;17:103–15.
132. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol*. 2016;17:984–93.
133. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med*. 2017;23:703–13.
134. Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. *Acta Pharm Sin B*. 2019;9:871–9.
135. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature*. 2013;503:548–51.
136. Black RC, Khurshid H. NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance. *R I Med J*. 2015;98:25–28.
137. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. *New Engl J Med*. 2021;384:2371–81.

138. Janne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. *New Engl J Med*. 2022;387:120–31.
139. Fausti F, Di Agostino S, Sacconi A, Strano S, Blandino G. Hippo and *rassf1a* pathways: a growing affair. *Mol Biol Int*. 2012;2012:307628.
140. Gao H, Yang J, He L, Wang W, Liu Y, Hu Y, et al. The diagnostic potential of SHOX2 and RASSF1A DNA methylation in early lung adenocarcinoma. *Front Oncol*. 2022;12:849024.
141. Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, et al. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. *Cancer Res*. 2003;63:6206–11.
142. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *J Am Med Assoc*. 2014;311:1998–2006.
143. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *New Engl J Med*. 2013;368:2385–94.
144. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *New Engl J Med*. 2014;371:2167–77.
145. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet*. 2017;389:917–29.
146. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *New Engl J Med*. 2017;377:829–38.
147. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. *New Engl J Med*. 2018;379:2027–39.
148. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. *New Engl J Med*. 2020;383:2018–29.
149. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. *Sci Transl Med*. 2012;4:120ra117.
150. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. *Cancer Discov*. 2017;7:137–55.
151. Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. *Nat Cancer*. 2023;4:330–43.
152. Tsuji T, Ozasa H, Aoki W, Aburaya S, Yamamoto Funazo T, Furugaki K, et al. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. *Nat Commun*. 2020;11:74.
153. Dardaie L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. *Nat Med*. 2018;24:512–7.
154. Kim MK, Park JY, Kang YN. Tumorigenic role of YAP in hepatocellular carcinogenesis is involved in SHP2 whose function is different in vitro and in vivo. *Pathol Res Pr*. 2018;214:1031–9.
155. Ou SH, Tan J, Yen Y, Soo RA. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. *Expert Rev Anticancer Ther*. 2012;12:447–56.
156. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. *Biochim Biophys Acta*. 2009;1795:37–52.
157. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. *Clin Cancer Res*. 2013;19:4040–5.
158. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell*. 2007;131:1190–203.
159. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. *Oncologist*. 2013;18:865–75.
160. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*. 2012;30:863–70.
161. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. *Clin Cancer Res*. 2012;18:4570–9.
162. Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. *Ann Oncol*. 2013;24:2364–70.
163. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. *J Clin Oncol*. 2017;35:2613–8.
164. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *New Engl J Med*. 2014;371:1963–71.
165. Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. *Lancet Oncol*. 2020;21:261–70.
166. Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. *Lancet Oncol*. 2019;20:1691–701.
167. Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, et al. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer. *Cancer Sci*. 2023;114:546–60.
168. Moroishi T, Hayashi T, Pan WW, Fujita Y, Holt MV, Qin J, et al. The Hippo pathway kinases LATS1/2 suppress cancer immunity. *Cell*. 2016;167:1525–39.e1517.
169. Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z, et al. YAP is essential for treg-mediated suppression of antitumor immunity. *Cancer Discov*. 2018;8:1026–43.
170. Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, et al. The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. *Cancer Res*. 2018;78:1457–70.
171. Taha Z, Janse van Rensburg HJ, Yang X. The Hippo pathway: immunity and cancer. *Cancers*. 2018;10:94.
172. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. *Sci Signal*. 2014;7:ra42.
173. Feng J, Yang H, Zhang Y, Wei H, Zhu Z, Zhu B, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. *Oncogene*. 2017;36:5829–39.
174. Passaro A, Brahmeh J, Antonia S, Mok T, Peters S. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. *J Clin Oncol*. 2022;40:598–610.
175. Hsu PC, Yang CT, Jablons DM, You L. The role of Yes-associated protein (YAP) in regulating programmed death-ligand 1 (PD-L1) in thoracic cancer. *Biomedicines*. 2018;6:114.
176. Lee BS, Park DI, Lee DH, Lee JE, Yeo MK, Park YH, et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. *Biochem Biophys Res Commun*. 2017;491:493–9.
177. Miao J, Hsu PC, Yang YL, Xu Z, Dai Y, Wang Y, et al. YAP regulates PD-L1 expression in human NSCLC cells. *Oncotarget*. 2017;8:114576–87.
178. Kim EH, Sohn BH, Eun YG, Lee DJ, Yim SY, Kang SG, et al. Silence of Hippo pathway associates with pro-tumoral immunosuppression: potential therapeutic target of glioblastomas. *Cells*. 2020;9:1761.
179. Liu C, Song Y, Li D, Wang B. Regulation of the tumor immune microenvironment by the Hippo pathway: implications for cancer immunotherapy. *Int Immunopharmacol*. 2023;122:110586.
180. Yoo G, Park D, Kim Y, Chung C. New insights into the clinical implications of Yes-associated protein in lung cancer: roles in drug resistance, tumor immunity, autophagy, and organoid development. *Cancers*. 2021;13:3069.
181. Choi JY, Lee H, Kwon EJ, Kong HJ, Kwon OS, Cha HJ. TGFbeta promotes YAP-dependent AXL induction in mesenchymal-type lung cancer cells. *Mol Oncol*. 2021;15:679–96.
182. Du D, Cao X, Duan X, Zhang X. Blocking circ_0014130 suppressed drug resistance and malignant behaviors of docetaxel resistance-acquired NSCLC cells via regulating miR-545-3p-YAP1 axis. *Cytotechnology*. 2021;73:571–84.
183. Zheng Y, Yang X, Tan J, Tian R, Shen P, Cai W, et al. Curcumin suppresses the stemness of non-small cell lung cancer cells via promoting the nuclear-cytoplasm translocation of TAZ. *Environ Toxicol*. 2021;36:1135–42.
184. Wang Y, Li F, Ma D, Gao Y, Li R, Gao Y. MicroRNA-608 sensitizes non-small cell lung cancer cells to cisplatin by targeting TEAD2. *Mol Med Rep*. 2019;20:3519–26.
185. Zheng L, Luo C, Yang N, Pei H, Ji M, Shu Y, et al. Ionizing radiation-induced long noncoding RNA CRYBG3 regulates YAP/TAZ through mechanotransduction. *Cell Death Dis*. 2022;13:209.
186. Li J, Zhang X, Hou Z, Cai S, Guo Y, Sun L, et al. P130cas-FAK interaction is essential for YAP-mediated radioresistance of non-small cell lung cancer. *Cell Death Dis*. 2022;13:783.
187. Li Y, Sun C, Tan Y, Zhang H, Li Y, Zou H. ITGB1 enhances the radioresistance of human non-small cell lung cancer cells by modulating the DNA damage response and YAP1-induced epithelial-mesenchymal transition. *Int J Biol Sci*. 2021;17:635–50.
188. Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. *Clin Sci*. 2022;136:197–222.
189. Yu M, Chen Y, Li X, Yang R, Zhang L, Huangfu L, et al. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD. *Cell Death Dis*. 2018;9:464.
190. Huang H, Zhang W, Pan Y, Gao Y, Deng L, Li F, et al. YAP suppresses lung squamous cell carcinoma progression via deregulation of the DNP63-GPX2 axis and ROS accumulation. *Cancer Res*. 2017;77:5769–81.

191. Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, et al. Structural insights into the YAP and TEAD complex. *Genes Dev.* 2010;24:235–40.
192. Nowak-Sliwinska P, Weiss A, van Beijnum JR, Wong TJ, Ballini JP, Lovisa B, et al. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. *J Cell Mol Med.* 2012;16:1553–62.
193. Karim SP, Adelman RA. Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. *Clin Ophthalmol.* 2013;7:1867–75.
194. Pobbati AV, Han X, Hung AW, Weiguang S, Huda N, Chen GY, et al. Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. *Structure.* 2015;23:2076–86.
195. Noland CL, Gierke S, Schnier PD, Murray J, Sandoval WN, Sagolla M, et al. Palmitoylation of TEAD transcription factors is required for their stability and function in hippo pathway signaling. *Structure.* 2016;24:179–86.
196. Barry ER, Simov V, Valtingoer I, Venier O. Recent therapeutic approaches to modulate the hippo pathway in oncology and regenerative medicine. *Cells.* 2021;10:2715.
197. Lu W, Wang J, Li Y, Tao H, Xiong H, Lian F, et al. Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitylation inhibitors. *Eur J Med Chem.* 2019;184:111767.
198. Holden JK, Crawford JJ, Noland CL, Schmidt S, Zbieg JR, Lacap JA, et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of Hippo pathway signaling. *Cell Rep.* 2020;31:107809.
199. Tang TT, Konradi AW, Feng Y, Peng X, Ma M, Li J, et al. Small molecule inhibitors of TEAD auto-palmitoylation selectively inhibit proliferation and tumor growth of NF2-deficient mesothelioma. *Mol Cancer Ther.* 2021;20:986–98.
200. Lu T, Li Y, Lu W, Spitters T, Fang X, Wang J, et al. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3. *Acta Pharm Sin B.* 2021;11:3206–19.
201. Tang TT, Post L. Abstract 5364: The TEAD autopalmitylation inhibitor VT3989 improves efficacy and increases durability of efficacy of osimertinib in preclinical EGFR mutant tumor models. *Cancer Res.* 2022;82:5364.
202. Yap TA, Kwiatkowski DJ, Desai J, Dagogo-Jack I, Millward M, Kindler HL, et al. First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. *AACR Annual Meeting.* 2023. <https://www.abstractsonline.com/pp8/#!/10828/presentation/10247>.
203. Yap TA, Kwiatkowski DJ, Desai J, Dagogo-Jack I, Millward M, Kindler HL, et al. VT3989 May Be Safe Effective in Patients With Advanced Mesothelioma and NF2 Mutant Solid Tumors. *The ASCO Post.* 2023. <https://ascopost.com/news/april-2023/vt3989-may-be-safe-effective-in-patients-with-advanced-mesothelioma-and-nf2-mutant-solid-tumors>.
204. Haderk F, Fernández-Méndez C, Čech L, Yu J, Meraz IM, Olivas V, et al. A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer. *bioRxiv* 2021.10.23.465573. Published online October 24, 2021. <https://doi.org/10.1101/2021.10.23.465573>.
205. Sun Y, Hu L, Tao Z, Jarugumilli GK, Erb H, Singh A, et al. Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells. *Nat Commun.* 2022;13:6744.
206. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the Cancer Genome Atlas. *Cell.* 2018;173:321–37.e310.
207. Seavey CN, Pobbati AV, Hallett A, Ma S, Reynolds JP, Kanai R, et al. WWTR1(TAZ)-CAMTA1 gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis. *Genes Dev.* 2021;35:512–27.
208. Tanas MR, Sboner A, Oliveira AM, Erickson-Johnson MR, Hespelt J, Hanwright PJ, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. *Sci Transl Med.* 2011;3:98ra82.
209. Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, et al. Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. *BMC Cancer.* 2011;11:523.
210. Drexler R, Kuchler M, Wagner KC, Reese T, Feyerabend B, Kleine M, et al. The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma. *J Cancer Res Clin Oncol.* 2021;147:373–91.
211. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell.* 2014;157:1262–78.
212. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science.* 2014;346:1258096.
213. Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, et al. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. *Adv Drug Deliv Rev.* 2021;176:113891.
214. Wang C, Zhang Y, Wu Y, Xing D. Developments of CRBN-based PROTACs as potential therapeutic agents. *Eur J Med Chem.* 2021;225:113749.
215. Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A, et al. Binary pancreatic cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer Cell.* 2021;39:1115–34.e1112.

ACKNOWLEDGEMENTS

The authors would like to express their gratitude to EditSprings (<https://www.editsprings.cn>) for the expert linguistic services provided.

AUTHOR CONTRIBUTIONS

HL and MW conceived and designed the review protocol. HL, YX, JZ, and MC conducted a systematic literature collection. HL summarized and wrote the manuscript. MW revised the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41417-024-00761-z>.

Correspondence and requests for materials should be addressed to Mengzhao Wang.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024